Drugs / CYT-108
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06263270 Comparator | Jun 2024 → Mar 2025 | osteoarthritis, knee | Cytonics Corporation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CYT-108 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06263270 ↗ |
| Modality | Protein / enzyme biologic | “CYT-108 is a recombinant alpha-2-macroglobulin (A2M) variant” NCT06263270 ↗ |
| Route | Other | “5mL (five milliliters) intra-articular injections of CYT-108 (5mg/mL)” NCT06263270 ↗ |